Related Experiment Videos
Oxatomide plasma levels in man during chronic dosing
Pharmatherapeutica
|January 1, 1983
Abstract:
A study was carried out in 8 subjects to measure plasma levels of oxatomide at defined intervals after chronic dosing with 30 mg twice daily for a period of 22 days. Plasma oxatomide levels were measured by radioimmunoassay. The results showed that mean steady-state plasma levels of 20 to 30 ng/ml just before the next dose and approximately 40 ng/ml 4 hours after a dose were reached by the sixth day of dosing.
Insights
This study measured oxatomide plasma levels in 8 subjects over 22 days. Steady-state levels were reached by day six, indicating consistent drug accumulation during chronic dosing.
Area of Science:
- Pharmacokinetics
- Drug Metabolism and Transport
Background:
- Oxatomide is an antihistamine medication.
- Understanding its pharmacokinetic profile is crucial for effective therapeutic use.
Purpose of the Study:
- To determine steady-state plasma concentrations of oxatomide.
- To evaluate the time course of oxatomide levels during chronic oral administration.
Main Methods:
- A radioimmunoassay technique was employed for plasma oxatomide quantification.
- Eight healthy subjects received 30 mg of oxatomide twice daily for 22 days.
Main Results:
- Mean steady-state plasma oxatomide levels reached 20-30 ng/ml just before the next dose.
- Peak plasma levels of approximately 40 ng/ml were observed 4 hours post-dose.
- These steady-state levels were achieved by the sixth day of treatment.
Conclusions:
- Chronic dosing of oxatomide at 30 mg twice daily leads to predictable steady-state plasma levels.
- The pharmacokinetic data suggest consistent absorption and accumulation of oxatomide over time.